Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive News A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHWritten by Nathan Reiff. Published: 2/12/2026. 
At a Glance - AstraZeneca, Edwards Lifesciences, and Zimmer Biomet all reported earnings on the same day, but with vastly different results.
- Of these, AstraZeneca's impressive oncology medicine sales growth stands out, having driven significant top-line growth.
- Edwards and Zimmer both saw notable successes in the latest quarter, but also face sizable challenges.
More than a simple financial check-up, earnings from companies in the healthcare sector give investors a window into a firm's drug pipeline and development progress. Even well-established healthcare companies can surprise with renewed growth after a new blockbuster drug or device, and earnings seasons often include management commentary that provides context beyond FDA approval notices. When multiple healthcare companies report on the same day, investors must quickly sort the news to plan trades. On Feb. 10, 2026, three major names in the sector—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—each released full-year and Q4 2025 results. Below are highlights and takeaways for healthcare investors. AstraZeneca Firms Up Cancer Business in a Strong Overall Quarterly Performance Wall Street Journal best-selling author James Altucher has uncovered a way to get a pre-IPO stake BEFORE Starlink goes public.
All it takes is just a few minutes of time and as little as $100 to get started. Plus, you can take action right inside your regular brokerage account. Click here now to see how to take action. U.K.-based pharma giant AstraZeneca closed out 2025 by further cementing its position in oncology, which accounted for about 44% of product sales in the quarter. Sales of key cancer drugs such as Imfinzi and Enhertu rose as much as 48% year-over-year (YOY), helping drive total revenue up 8.6% to $58.7 billion for the year. After-tax profits climbed alongside revenue, rising to $10.2 billion from $7 billion in the prior-year quarter. The company's board declared a second interim dividend that was 7 cents higher than last year's. Investors also have a busy pipeline to watch: management said 20 Phase 3 readouts are expected in 2026. AstraZeneca reiterated expectations for solid increases in both total revenue and core earnings per share (EPS) for full-year 2026. In the hours after its earnings release, AZN shares climbed roughly 3%. Despite 10 of 11 analysts rating AZN a Buy or equivalent, the consensus price target of $95.75 implies about a 51% downside from the then-current share price, highlighting valuation concerns among some investors. TAVR Momentum Fuels Edwards Sales Growth, Though Investors Should Watch Margins Edwards makes replacement heart valves and related surgical devices and monitoring systems. Its Q4 2025 results were largely positive: sales rose 13.3% YOY, driven by strong transcatheter aortic valve replacement (TAVR) momentum and demand for the newest SAPIEN valve. However, adjusted EPS missed analyst expectations and gross profit margin declined 0.8% YOY. Despite the mixed quarter, Edwards remained confident it could meet its 2026 outlook, which forecast sales growth of 8%–10% YOY and EPS of $2.90–$3.05. EW shares rose about 4% to trade above $80 in after-hours trading following the announcement. About two-thirds of analysts covering EW rate the stock a Buy, and the consensus price target suggests roughly 25% upside to $96.77. Orthopedic Demand Remains High, But Zimmer Faces Some Headwinds Going Forward Zimmer Biomet, which makes joint replacement systems and orthopedic implants, saw its shares rise more than 3% in the hours after reporting EPS of $2.42—$0.04 above consensus—and revenue of $2.2 billion, up nearly 11% YOY and slightly ahead of expectations. Solid demand for its orthopedic products supported both top- and bottom-line growth. The company is shifting to concentrate more on U.S. sales, where it derives nearly 60% of revenue. With insured patient utilization continuing to climb, demand for Zimmer's products is expected to remain strong in the near term. That said, Zimmer expects tariffs to continue to pressure results, which helped drive conservative guidance in the latest earnings report. Management projected adjusted EPS of $8.30–$8.45 and forecast free cash flow improvement of 8%–10% for 2026. Prior to the earnings release, analysts were divided on Zimmer, assigning an overall Hold rating despite about 15% projected upside.
| 
